Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
Recruiting · NCT06633354 · Registry updated 2024-10-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Early phase 1 | 2024-10-09 | NCT06633354 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Yake Biotechnology Ltd. | 30 |
| Zhejiang University | 194 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The first affiliated hospital of medical college of zhejiang university | Hangzhou | China | 13 |